RxDoctor Payments DataLook up a doctor →

Joseph Eron, MD

Infectious Disease · Chapel Hill, NCNPI 1598838336

Payments from drug & device makers

$1,101,120in general payments, 2019–2025

Across 502 payments — averaging $2193.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$600K
  • Viiv Healthcare Company$300K
  • Janssen Research & Development, LLC$101K
  • Merck$87K
  • GSK$5K
  • Janssen Scientific Affairs, LLC$4K
  • plus $5K from 2 others

What the payments were for

  • Royalty or licence$2620%
  • Consulting fees$159,78182%
  • Speaking & faculty fees$3,1822%
  • Grants$4,2272%
  • Travel & lodging$24,92013%
  • Food & beverage$3,0022%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead221$599,556
Viiv Healthcare Company157$299,731
Janssen Research & Development, LLC30$100,610
Merck84$86,870
GSK3$5,025
Janssen Scientific Affairs, LLC4$4,489
Shionogi Inc2$3,189
AbbVie1$1,650

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101,120 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,446
Medicare patients
43
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala144$593,699
OdefseyEmtricitab/Rilpiviri/Tenof Ala62$266,437
TivicayDolutegravir Sodium98$261,940
DescovyEmtricitabine/Tenofov Alafenam108$239,282
PifeltroDoravirine62$106,890
RukobiaFostemsavir Tromethamine12$103,138
CabenuvaCabotegravir/Rilpivirine14$88,504
PrezcobixDarunavir/Cobicistat35$87,269
DovatoDolutegravir Sodium/Lamivudine25$71,881
JulucaDolutegravir/Rilpivirine19$66,264
IsentressRaltegravir Potassium17$34,259
Maraviroc13$13,911
OzempicSemaglutide11$10,484
NorvirRitonavir14$3,510
Ritonavir14$2,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$599,556$832,981252 claims
Viiv Healthcare CompanyTivicay, Rukobia, Cabenuva, Dovato, Juluca$299,731$591,727168 claims
MerckPifeltro, Isentress$86,870$141,14979 claims
AbbVieNorvir$1,650$3,51014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →